PROTOCOL ALERT New Clinical Trials Recently Added to the National Cancer Institute’s Database BLADDER CANCER Phase 1/1b Study to Evaluate the Safety Trial IDs: 556-15, NCI-2015-01502, and Tolerability of CPI-444 Alone and NCT02553447 Type: Biomarker/Laboratory analysis, A Study Of Avelumab In Patients in Combination With Atezolizumab in Treatment With Locally Advanced Or Metastatic Advanced Cancers Ibrutinib in Treating Minimal Residual Age: 18 to 75 Urothelial Cancer (JAVELIN Bladder Status: Active Disease in Patients With Chronic Trial IDs: UW14113, NCI-2015-02269, 100) Phase: Phase I Lymphocytic Leukemia After Front- 2015-0996, NCT02652468 Status: Active Type: Treatment Line Therapy Phase: Phase III Age: 18 and over Status: Active ESOPHAGEAL CANCER Type: Treatment Trial IDs: CPI-444-001, NCI-2016- Phase: Phase II Age: 18 and over 00227, NCT02655822 Type: Biomarker/Laboratory analysis, Proton Beam Radiation Therapy Trial IDs: B9991001, NCI-2016-00304, Treatment or Intensity-Modulated Radiation 2015-003262-86, JAVELIN Bladder 100, Circulating Tumor Cells in Operative Age: 18 and over Therapy in Treating Patients With NCT02603432 Blood in Patients With Bladder Cancer Trial IDs: MC1481, NCI-2015-02153, Esophageal Cancer Status: Not yet active NCT02649387 Status: Active A Study of Intravesical Apaziquone Phase: No phase specified Phase: Phase III as a Surgical Adjuvant in Patient Type: Biomarker/Laboratory analysis, Ibrutinib or Idelalisib in Treating Type: Treatment Undergoing TURBT Natural history/Epidemiology Patients With Persistent or Relapsed Age: 18 and over Status: Active Age: 18 and over Chronic Lymphocytic Leukemia, Small Trial IDs: 2011-1036, NCI-2012-00078, Phase: Phase III Trial IDs: 4B-15-7, NCI-2015-01063, Lymphocytic Lymphoma, or Non- NCT01512589 Type: Treatment NCT02514408 Hodgkin Lymphoma After Donor Stem Age: 18 and over Cell Transplant Glutamine in Reducing the Severity of Trial IDs: SPI-EOQ-13-305, NCI-2016- Status: Not yet active Mucositis or Esophagitis in Patients CHRONIC LYMPHOCYTIC 00340, NCT02563561 Phase: Phase II With Advanced Cancer Receiving LEUKEMIA Type: Treatment mTOR Inhibitor-Based Chemotherapy A Study to Evaluate the Efficacy Ublituximab + TGR-1202 Compared Age: 18 and over or Radiation Therapy and Safety of Rivaroxaban Venous to Obinutuzumab + Chlorambucil in Trial IDs: 2561.00, NCI-2015-02201, Status: Active Thromboembolism (VTE) Prophylaxis Patients With Chronic Lymphocytic NCT02662296 Phase: Phase III in Ambulatory Cancer Participants Leukemia Type: Supportive care Status: Active Status: Active Study of EDO-S101, A First-in-Class Age: Not specified Phase: Phase III Phase: Phase III Alkylating HDACi Fusion Molecule, Trial IDs: 2013-0308, NCI-2014-00917, Type: Prevention Type: Treatment in Relapsed/Refractory Hematologic NCT01952847 Age: 18 and over Age: 18 and over Malignancies Trial IDs: CR107047, NCI-2016-00410, Trial IDs: UTX-TGR-304, NCI-2016- Status: Not yet active Early Palliative Care With Standard 2015-001630-21, 39039039STM4001, 00375, NCT02612311 Phase: Phase I Care or Standard Care Alone in NCT02555878 Type: Biomarker/Laboratory analysis, Improving Quality of Life of Patients Abatacept, Cyclosprine, Tacrolimus, Treatment With Incurable Lung or Non-colorectal Study of Pembrolizumab (MK-3475) and Methotrexate in Preventing Graft- Age: 18 and over Gastrointestinal Cancer and Their in Participants With High Risk Non- versus-Host Disease in Patients with Trial IDs: EDO-S101-1001, NCI-2016- Family Caregivers muscle Invasive Bladder Cancer High-Risk Leukemia Undergoing Stem 00310, NCT02576496 Status: Active (MK-3475-057/KEYNOTE-057) Cell Transplant Phase: Phase III Status: Active Status: Active Laboratory-Treated T Cells in Treating Type: Supportive care Phase: Phase II Phase: Phase II Patients with B-cell Lymphoma, Age: 18 and over Type: Treatment Type: Supportive care Chronic Lymphocytic Leukemia, or Trial IDs: A221303, NCI-2014-01943, Age: 18 and over Age: 6 and over Acute Lymphocytic Leukemia NCT02349412 Trial IDs: 3475-057, NCI-2016-00312, Trial IDs: 2692.00, NCI-2016-00220, Status: Active 2014-004026-17, NCT02625961 PBMTC PROTOCOL GVH 1201, Phase: Phase I A Study of BBI608 Administered NCT01743131 Type: Biomarker/Laboratory analysis, With Paclitaxel in Adult Patients With Trastuzumab Emtansine in Treating Treatment Advanced Malignancies Patients with HER2 Amplified or CXCR4 Antagonist BL-8040 in Age: 18 to 73 Status: Active Mutant Advanced Cancers Mobilizing Stem Cells for Donor Trial IDs: 16-C-0054, NCI-2016-00101, Phase: Phase II, Phase I Status: Active Transplant in Healthy Donors and P152152, NCT02659943 Type: Treatment Phase: Phase II Patients With Advanced Hematological Age: 18 and over Type: Biomarker/Laboratory analysis, Malignancies Genetically Modified T-Cell Trial IDs: BBI608-201, NCI-2014-01566, Treatment Status: Not yet active Therapy in Treating Patients NCT01325441 Age: 18 and over Phase: Phase II With Advanced ROR1+ Trial IDs: 15-335, NCI-2016-00262, Type: Biomarker/Laboratory analysis, Malignancies A Phase Ib Study of MEK162 Plus NCT02675829 Treatment Status: Not yet active BYL719 in Adult Patients With Selected Age: 18 to 75 Phase: Phase I Advanced Solid Tumors Paclitaxel Albumin-Stabilized Trial IDs: 201602037, NCI-2016-00197, Type: Biomarker/Laboratory analysis, Status: Active Nanoparticle Formulation after NCT02639559 Treatment Phase: Phase II, Phase I Cisplatin-Based Chemotherapy and Age: 18 and over Type: Treatment Surgery in Treating Patients With Cholecalciferol in Treating Patients Trial IDs: 9330, NCI-2015-01753, Age: 18 and over High-Risk Bladder Cancer with Newly Diagnosed Non-Hodgkin 9330A, NCT02706392 Trial IDs: CMEK162X2109, NCI-2012- Status: Not yet active Lymphoma or Chronic Lymphocytic 00874, 2011-002578-21, NCT01449058 Phase: Phase II Leukemia with Vitamin D Deficiency Donor TCR Alpha-Beta and CD19- Type: Biomarker/Laboratory analysis, Status: Active Depleted Stem Cell Transplant in Probiotic LGG for Prevention of Treatment Phase: Phase II Treating Patients With Relapsed or Side Effects in Patients Undergoing Age: 18 and over Type: Biomarker/Laboratory analysis, Refractory Lymphomas Chemoradiation for Gastrointestinal Trial IDs: MC1551, NCI-2016-00133, Treatment Status: Active Cancer NCT02718742 Age: 19 and over Phase: No phase specified Status: Active 32 Oncology Times April 25, 2016 Phase: Phase III Trial IDs: ADN011, NCI-2016-00165, Status: Active PROTOCOL ALERT Type: Biomarker/Laboratory analysis, 2015-001360-19, NCT02411084 Phase: Phase III continued from page 32 Supportive care, Treatment Type: Treatment Age: not specified Safety Follow-up of Treatment With Age: 18 to 70 Trial IDs: 2448.00, NCI-2010-02035, Remestemcel-L in Pediatric Patients Trial IDs: BMTCTN1101, NCI-2014- Phase: Phase II, Phase I NCT01231412 Who Have Failed to Respond to Steroid 00307, 2U10HL069294-11, 715, Type: Supportive care, Treatment Treatment for Acute GVHD NCT01597778 Age: 18 and over P3 Study of Umbilical Cord Blood Status: Active Trial IDs: 201404101, NCI-2013-00650, Cells Expanded With MPCs for Phase: Phase III Phase 3 Frontline Therapy Trial in NCT01790035 Transplantation in Patients With Type: Natural history/Epidemiology, Patients With Advanced Classical Hematologic Malignancies Treatment Hodgkin Lymphoma Study of Carfilzomib With Irinotecan Status: Active Age: 2 months to 17 years Status: Enrolling by invitation in Irinotecan-Sensitive Malignancies Phase: Phase III Trial IDs: MSB-GVHD002, NCI-2016- Phase: Phase III and Small Cell Lung Cancer Patients Type: Treatment 00303, NCT02652130 Type: Treatment Status: Active Age: 65 and under Age: 18 and over Phase: Phase II, Phase I Trial IDs: CB-AB006, NCI- Donor Peripheral Blood Stem Trial IDs: C25003, NCI-2012-03101, Type: Biomarker/Laboratory analysis, 2013-00758, 2012-0166, Cell transplantation Followed by 12/LO/1950, 2011-005450-60, Treatment NCT01854567 Lenalidomide and Sirolimus in JapicCTI-142491, U1111-1161-4937, Age: 18 and over Treating Patients With High-Risk NCT01712490 Trial IDs: CRAB CTC 11-001, NCI- Blinatumomab in Treating Younger Multiple Myeloma 2014-02260, CAR-IST-553, NCI-2013- Patients With Relapsed B-cell Acute Status: Active P3 Study of Umbilical Cord Blood 02243, NCT01941316 Lymphoblastic Leukemia Phase: Phase II, Phase I Cells Expanded With MPCs for Status: Active Type: Supportive care, Treatment Transplantation in Patients With HuMax®-TF-ADC Safety Study in Phase: Phase III Age: 18 to 70 Hematologic Malignancies Patients With Solid Tumors Type: Biomarker/Laboratory analysis, Trial IDs: IUCRO-0307, NCI- Status: Active Status: Active Treatment 2011-00266, 1012-24, 1105005328, Phase: Phase III Phase: Phase II, Phase I Age: 1 to 30 NCT01303965 Type: Treatment Type: Biomarker/Laboratory analysis, Trial IDs: AALL1331, NCI-2014-00631, Age: 65 and under Treatment COG-AALL1331, NCT02101853 Donor Cytokine-Induced Killer Trial IDs: CB-AB006, NCI-2013-00758, Age: 18 and over Cells in Treating Patients With 2012-0166, NCT01854567 Trial IDs: GEN701, NCI-2014-01166, Calcineurin Inhibitor-Free Myelodysplasia or Myeloproliferative NCT02001623 Interventions for Prevention of Graft- Disorders Previously Treated With A Study to Evaluate a Therapeutic Versus-Host Disease (BMT CTN 1301) Donor Stem Cell Transplant Vaccine, ASP0113, in Cytomegalovirus Vaccine Therapy and Iscomatrix With Status: Active Status: Active (CMV)-Seropositive Recipients or Without Cyclophosphamide and Phase: Phase III Phase: Phase II, Phase I Undergoing Allogeneic, Hematopoietic Celecoxib in Treating Patients With Type: Treatment